Lupin Signs Exclusive Distribution Pact with ForDoz Pharma for 2 Complex Injectable Assets Under Development

Mumbai, Baltimore, August 06, 2020: Pharma major Lupin Limited (Lupin) announced today that its U.S. based wholly-owned subsidiary Lupin Inc. has entered into an agreement with ForDoz Pharma Corp (ForDoz) for granting Lupin the exclusive rights to market and distribute 2 complex injectable assets in advanced stages of development in the U.S. and its territories.

The two assets are in the Oncology and Anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.

The assets will be manufactured in ForDoz’s U.S. based manufacturing site and ForDoz will be responsible for the development, and obtaining the necessary regulatory approvals. Lupin shall leverage its existing commercial infrastructure for marketing and distribution of the two assets.

Commenting on the development Alok Sonig, CEO, US Generics and Global Head, Generics R&D and Biosimilars for Lupin said, “The partnered assets are a key, strategic addition to our complex injectables pipeline and will bolster our Institutional business offering. These assets will complement Lupin’s ongoing organic R&D efforts in complex assets including inhalation and long-acting injectables as well as Biosimilars.”

According to James He, Founder and CEO for ForDoz Pharma Corp, “ForDoz Pharma is excited to partner our complex injectable flagship products with Lupin. Lupin’s leadership presence in U.S. will complement ForDoz’s scientific and complex injectable manufacturing capability to bring affordable medicines to patients in an efficient manner”.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

About ForDoz

ForDoz Pharma Corporation is a privately-owned specialty pharmaceutical company focusing on development, manufacturing, and commercialization of value-added sterile and complex injectable products such as liposomes, microspheres, micelles, nanosuspensions, and microcrystal-suspensions.

ForDoz Pharma is located in the 27-acre campus at greater Princeton area of New Jersey, a prominent pharmaceutical hub in the United States. At this 27-acre campus, ForDoz has R&D labs, cGMP QC and microbiology labs and a fully qualified and validated sterile complex injectable product manufacturing facility which complies with both US and EU cGMP standards.

ForDoz Pharma is accelerating and improving traditional drug development processes through proprietary particle-based drug delivery technology platform with particle sizes ranging from 10 nm to several µm. At ForDoz Pharma, we can commercialize products as a CDMO partner via a closed loop system, from R&D, analytical testing, process scale-up to commercial manufacturing all from our one single campus.

Please visit www.fordozpharma.com for more information

LinkedIn: www.linkedin.com/company/fordoz-pharma-corp/

For further information or queries please contact: